Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c
Conditions
Interventions
NX210c
Placebo
Locations
16
France
Centre Hospitalier Regional Et Universitaire De Brest
Brest, France, France
Centre Hospitalier Universitaire De Caen Normandie
Caen, France, France
Hôpital La Timone - APHM
Marseille, France, France
CHRU De Nancy
Nancy, France, France
Centre Hospitalier Universitaire d'Angers
Angers, France
Centre Hospitalier Universitaire De Bordeaux
Bordeaux, France
Start Date
October 25, 2024
Primary Completion Date
February 1, 2026
Completion Date
September 30, 2026
Last Updated
December 24, 2025
NCT05204017
NCT07322003
NCT07414212
NCT07401121
NCT05104710
NCT03233646
Lead Sponsor
Axoltis Pharma
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions